| Module ID |
Description |
# of Compounds |
|
A2H |
Salmonella Ames Mutagenicity updated from NTP, GENETOX, FDA
and others |
5864 |
|
A99 |
Salmonella Mutagenicity of Pesticides |
55 |
|
A9L |
Salmonella mutation GeneTox 2003 (SAL+/- S9) |
706 |
|
A9M |
Salmonella mutation NTP 2003 (SAL+/- S9) |
1549 |
|
A2N |
Salmonella typhimurium (TA97) mutation in absence of S9 |
1007 |
|
A2O |
Salmonella typhimurium (TA98) mutation in absence of S9 |
3456 |
|
A2P |
Salmonella typhimurium (TA100) mutation in absence of S9 |
3781 |
|
A9A |
Salmonella typhimurium (TA102) mutation in absence of S9 |
522 |
|
A9B |
Salmonella typhimurium (TA104) mutation in absence of S9 |
276 |
|
A2L |
Salmonella typhimurium (TA1535) mutation in absence of S9 |
2051 |
|
A2M |
Salmonella typhimurium (TA1537) mutation in absence of S9 |
1558 |
|
A9C |
Salmonella typhimurium (TA1538) mutation in absence of S9 |
646 |
|
A2T |
Salmonella typhimurium (TA97) mutation in presence of Hamster
S9 |
639 |
|
A2U |
Salmonella typhimurium (TA98) mutation in presence of Hamster
S9 |
1673 |
|
A2P |
Salmonella typhimurium (TA100) mutation in presence of
Hamster S9 |
1662 |
|
A9D |
Salmonella typhimurium (TA102) mutation in presence of
Hamster S9 |
39 |
|
A9E |
Salmonella typhimurium (TA104) mutation in presence of
Hamster S9 |
33 |
|
A2R |
Salmonella typhimurium (TA1535) mutation in presence of
Hamster S9 |
1476 |
|
A2S |
Salmonella typhimurium (TA1537) mutation in presence of
Hamster S9 |
948 |
|
A9F |
Salmonella typhimurium (TA1538) mutation in presence of
Hamster S9 |
218 |
|
A2Y |
Salmonella typhimurium (TA97) mutation in presence of Rat S9 |
766 |
|
A2Z |
Salmonella typhimurium (TA98) mutation in presence of Rat S9 |
2983 |
|
A2V |
Salmonella typhimurium (TA100) mutation in presence of Rat S9 |
3214 |
|
A9G |
Salmonella typhimurium (TA102) mutation in presence of Rat S9 |
424 |
|
A9H |
Salmonella typhimurium (TA104) mutation in presence of Rat S9 |
216 |
|
A2W |
Salmonella typhimurium (TA1535) mutation in presence of Rat
S9 |
1757 |
|
A2X |
Salmonella typhimurium (TA1537) mutation in presence of Rat
S9 |
1469 |
|
A9I |
Salmonella typhimurium (TA1538) mutation in presence of Rat
S9 |
714 |
|
A2D |
Drosophila Mutation |
783 |
|
A6E |
E.Coli mutation (CCRIS) |
862 |
|
A6J |
Mouse lymphoma L5178Y (TK+/TK-) +/-S9 (NTP, GENETOX, CCRIS) |
910 |
|
A6O |
SOS Chromotest |
462 |
|
A7A |
FDA Mutagenicity Microbial composite (Sal_Ecoli_Bac) |
3682 |
|
A7B |
FDA Mutagenicity Salmonella t.
5-strains |
3573 |
|
A7C |
FDA Mutagenicity E.coli
composite |
526 |
|
A7D |
FDA Mutagenicity E.coli WP
strains |
279 |
|
A7E |
FDA Mutagenicity Yeast
composite |
603 |
|
A7F |
FDA Mutagenicity Yeast Sacharomyces
|
472 |
|
A7G |
FDA Mutagenicity Drosophila
composite |
591 |
|
A7H |
FDA Mutagenicity Drosophila sex linked
rec |
584 |
|
A7I |
FDA Mutagenicity Drosophila heritable
translocation |
115 |
|
A7J |
FDA Mutagenicity Mammal in vivo
composite |
214 |
|
A7K |
FDA Mutagenicity Mammal in vivo dominant
lethal |
182 |
|
A7O |
FDA Mutagenicity Mammal in vitro CHO V79
hgprt loci |
641 |
|
A7N |
FDA
genetic toxicity gene mutation In vitro mouse lymphoma L5178y Control
(research only) |
810* |
|
AN7 |
FDA
genetic toxicity gene mutation in vitro mouse lymphoma L5178Y A (research
only) |
566* |
|
AN8 |
FDA
genetic toxicity gene mutation in vitro mouse lymphoma L5178Y B (research
only) |
565* |
Salmonella TA97,TA98, TA100, TA102, TA104, TA1535, TA1537 and TA1538 strains
modules are developed with four different flavors: experimental
call, maximum fold, maximum effective concentration and rev/nmol.
* indicates modules updated or acquired in 2008.
Clastogenicity
| Module ID |
Description |
# of Compounds |
|
A60 |
NTP Sister Chromatid Exchange |
585 |
|
A61 |
NTP Chromosomal Aberration |
805 |
|
A62 |
Micronuclei Induction |
904 |
|
A6A |
Aneuploidy in Yeast |
93 |
|
A6N |
Sister Chromatid Exchanges - In Vivo |
176 |
|
A7P |
FDA Clastogenicity Chromosome abs in
vivo composite |
284 |
|
A7R |
FDA Clastogenicity Chromosome abs in
vivo Mouse |
152 |
|
A7S |
FDA Clastogenicity Micronucleus in vivo
composite |
820 |
|
A7T |
FDA Clastogenicity Micronucleus in vivo
mouse |
622 |
|
A7U |
FDA
Clastogenicity in vitro chromosome aberrations composite control (research
only) |
1394* |
|
A7V |
FDA
Clastogenicity in vitro chromosome aberrations CHO control (research
only) |
688* |
|
A7W |
FDA
Clastogenicity in vitro chromosome aberrations CHL control (research only) |
750* |
|
A7X |
FDA Clastogenicity in vitro human lymphocytes |
187* |
|
A7Y |
FDA Clastogenicity in vitro SCE composite control |
779* |
|
AY7 |
FDA Clastogenicity in vitro SCE composite part A |
412* |
|
AY8 |
FDA Clastogenicity in vitro SCE composite part B |
411* |
|
AY9 |
FDA Clastogenicity in vitro SCE composite part C |
411* |
|
A7Z |
FDA Clastogenicity in vitro SCE CHO |
626* |
|
A8I |
FDA Clastogenicity in vitro SCE other cell types |
204* |
|
A8J |
FDA Clastogenicity Micronucleus in vivo
undef. species |
441 |